Stanford University
Kavita Sari
The main goal of this protocol is to develop a well-phenotyped genetic biobank to identify genetic variants associated with the heterogeneous clinical presentations of Neurofibromatosis Type 1 (NF1). This will allow for improve understanding of NF1 pathogenesis and more personalized disease management. The investigators will conduct a GWAS analysis to identify common genetic risk variants associated with the development of cutaneous neurofibromas.
Neurofibromatosis 1
Study Type : | OBSERVATIONAL |
Estimated Enrollment : | 1000 participants |
Official Title : | Evaluating Genetic Modifiers of Cutaneous Neurofibromas in Adults with Neurofibromatosis Type 1 |
Actual Study Start Date : | 2021-05-07 |
Estimated Primary Completion Date : | 2025-09-30 |
Estimated Study Completion Date : | 2025-09-30 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 40 Years |
Sexes Eligible for Study: | ALL |
Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
Johns Hopkins University School of Medicine
Baltimore, California, United States, 21218
RECRUITING
Stanford University
Redwood City, California, United States, 94063